Stockscreener 앱 받기
7.72
2.28%
-0.18
시장 영업 전:
7.70
-0.02
-0.26%
전일 마감가:
$7.90
열려 있는:
$7.93
하루 거래량:
1.29M
Relative Volume:
0.97
시가총액:
$476.72M
수익:
$2.00M
순이익/손실:
$-51.04M
주가수익비율:
-4.8892
EPS:
-1.579
순현금흐름:
$-45.65M
1주 성능:
-11.77%
1개월 성능:
+45.11%
6개월 성능:
-0.64%
1년 성능:
+115.04%
1일 변동 폭
$7.47
$8.00
1주일 범위
$7.36
$8.85
52주 변동 폭
$3.08
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
명칭
Sagimet Biosciences Inc
전화
(650) 561-8600
주소
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
7.72 | 476.72M | 2.00M | -51.04M | -45.65M | -1.579 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-26 | 개시 | Rodman & Renshaw | Buy |
| 2026-02-03 | 개시 | Guggenheim | Buy |
| 2026-01-28 | 개시 | Barclays | Equal Weight |
| 2025-08-11 | 개시 | Wedbush | Outperform |
| 2025-08-07 | 재개 | H.C. Wainwright | Buy |
| 2025-07-24 | 개시 | Canaccord Genuity | Buy |
| 2024-12-06 | 개시 | Oppenheimer | Outperform |
| 2024-11-12 | 개시 | UBS | Buy |
| 2024-06-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-05-02 | 개시 | H.C. Wainwright | Buy |
| 2024-03-25 | 개시 | Leerink Partners | Outperform |
| 2023-08-08 | 개시 | Goldman | Buy |
| 2023-08-08 | 개시 | JMP Securities | Mkt Outperform |
| 2023-08-08 | 개시 | Piper Sandler | Overweight |
| 2023-08-08 | 개시 | TD Cowen | Outperform |
모두보기
Sagimet Biosciences Inc 주식(SGMT)의 최신 뉴스
Does Sagimet Biosciences Inc. (SGMT) have the potential to rally 241.77% as Wall Street analysts expect? - MSN
Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy? - sharewise.com
Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect? - Yahoo Finance
Sagimet Biosciences shares jump 30% on acne trial expansion plans - MSN
Sagimet Biosciences Price Target Raised to $49.00/Share From $28.00 by Canaccord Genuity - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Sagimet Biosciences | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Wedbush Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Oppenheimer Adjusts Price Target on Sagimet Biosciences to $33 From $28, Maintains Outperform Rating - marketscreener.com
Sagimet Therapeutics: Buy Rating Reiterated on Denifanstat’s First-Line Acne Potential; $28 Price Target Unchanged - TipRanks
Oppenheimer Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Raises Target Price to $33 - Moomoo
Sagimet Biosciences Targets Acne, Plans U.S. Phase III for Denifanstat After $175M Raise - MarketBeat
Guggenheim Lowers Sagimet Biosciences (NASDAQ:SGMT) Price Target to $25.00 - MarketBeat
Why Is Sagimet Biosciences Stock Trading Higher On Monday? - Sahm
Sagimet Biosciences offers 29.17 million shares of series A common stockSEC filing - marketscreener.com
Sagimet Biosciences Announces Major Equity Offering for Pipeline - TipRanks
Sagimet Biosciences | 424B5: Prospectus - Moomoo
Sagimet Biosciences | 8-K: Current report - Moomoo
Sagimet Biosciences (NASDAQ: SGMT) prices $164.5M equity raise to fund trials - Stock Titan
Sagimet Biosciences (NASDAQ: SGMT) raises $175M to fund Phase 3 denifanstat - Stock Titan
SGMT - Finviz
SGMT Stock Price, Quote & Chart | SAGIMET BIOSCIENCES INC-A (NASDAQ:SGMT) - ChartMill
Sagimet Biosciences rockets 30% on pricing $175M equity offering - MSN
Sagimet prices $175M stock offering to fund acne drug trials By Investing.com - Investing.com India
Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study - MSN
Sagimet Stock Surges as $175 Million Raise Sharpens Acne Drug Push - TechStock²
Sagimet prices $175M stock offering to fund acne drug trials - Investing.com UK
Why Sagimet Biosciences Stock Is Soaring Today - AOL.com
Oppenheimer raises Sagimet stock price target on acne focus - Investing.com UK
Oppenheimer raises Sagimet stock price target on acne focus By Investing.com - Investing.com South Africa
Sagimet Biosciences Shares Jump 30% on Acne Trial Expansion Plans - Yahoo Finance
SGMT stock surged 40% and breached 200-DMA for the first time in nearly 3 months – what’s got retail buzzing? - MSN
Sagimet Biosciences surges as $175M equity financing and acne-focused pipeline update reset the runway narrative - Quiver Quantitative
SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing? - Stocktwits
Sagimet Biosciences Advances Denifanstat and TVB-3567 as Novel FASN Inhibitors for Moderate to Severe Acne and MASH Treatment 23469 - Minichart
Sagimet Biosciences Advances Denifanstat and TVB-3567 as Novel FASN Inhibitors for Moderate to Severe Acne and MASH Treatment (2026 Update) - Minichart
Sagimet Biosciences (SGMT) Jumps As MASH Data Buzz Builds - StocksToTrade
Sagimet Biosciences to Fund Phase 3 Acne Trial in US With $175 Million Offering - marketscreener.com
Sagimet Biosciences SGMT Gains Attention On MASH Data - timothysykes.com
Sagimet plans U.S. Phase 3 acne trial in second half of 2026 - Investing.com UK
Morning Market Movers: SGMT, CMPX, ORKA, MANE See Big Swings - RTTNews
Sagimet Updates Investor Presentation After Key Clinical Milestones - TipRanks
Sagimet Highlights Pipeline Progress and Strategic Corporate Developments - TipRanks
Sagimet Biosciences stock surges 30% on acne trial plans By Investing.com - Investing.com South Africa
Sagimet plans U.S. Phase 3 acne trial in second half of 2026 By Investing.com - Investing.com South Africa
Sagimet Biosciences stock surges 30% on acne trial plans - Investing.com
Sagimet Biosciences to advance denifanstat to Phase 3 trial for U.S. acne market after China data - Traders Union
Sagimet Biosciences (SGMT) furnishes updated investor presentation via Form 8-K - Stock Titan
Sagimet Biosciences Inc. Prices Underwritten Offering of 29.2 Million Shares at $6.00 Each, Expected to Raise $175 Million - Quiver Quantitative
Sagimet raises $175M, says cash now funds acne programs through 2028 - Stock Titan
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock - GlobeNewswire
Sagimet Biosciences Inc (SGMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):